Orthocell Ltd
ASX:OCC

Watchlist Manager
Orthocell Ltd Logo
Orthocell Ltd
ASX:OCC
Watchlist
Price: 1.35 AUD -1.82% Market Closed
Market Cap: 322.8m AUD

Orthocell Ltd
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Orthocell Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Orthocell Ltd
ASX:OCC
Cash from Operating Activities
-AU$6.5m
CAGR 3-Years
-13%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Mesoblast Ltd
ASX:MSB
Cash from Operating Activities
-$48.5m
CAGR 3-Years
22%
CAGR 5-Years
3%
CAGR 10-Years
N/A
CSL Ltd
ASX:CSL
Cash from Operating Activities
$2.8B
CAGR 3-Years
-9%
CAGR 5-Years
11%
CAGR 10-Years
7%
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Cash from Operating Activities
AU$37.1m
CAGR 3-Years
24%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Telix Pharmaceuticals Ltd
ASX:TLX
Cash from Operating Activities
AU$23.9m
CAGR 3-Years
130%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
Cash from Operating Activities
-AU$38.6m
CAGR 3-Years
-48%
CAGR 5-Years
-50%
CAGR 10-Years
-28%

Orthocell Ltd
Glance View

Market Cap
322.8m AUD
Industry
Biotechnology

Orthocell Ltd. engages in the development and commercialization of cell therapies and related technologies. The company is headquartered in Perth, Western Australia. The company went IPO on 2014-08-12. The firm is engaged in the development and commercialization of cell therapies and biological medical devices. The firm offers two main products, including CelGro and Ortho-ATI. CelGro is a naturally derived collagen medical device, which is designed for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons and cartilage. The company represents a paradigm shift in bone and soft tissue reconstruction. Ortho-ATI is a cell therapy for treatment of chronic tendon injuries. The treatment uses patient’s own tendon-derived cells to stimulate tendon regeneration and is delivered via a non-surgical ultrasound guided injection. The firm has a Good Manufacturing Process (GMP) facility. The facility is licensed by the Therapeutic Goods Administration (TGA) for the manufacture of human tendon cells and cartilage cells for the regeneration of damaged tendon and cartilage.

OCC Intrinsic Value
0.53 AUD
Overvaluation 61%
Intrinsic Value
Price

See Also

What is Orthocell Ltd's Cash from Operating Activities?
Cash from Operating Activities
-6.5m AUD

Based on the financial report for Jun 30, 2024, Orthocell Ltd's Cash from Operating Activities amounts to -6.5m AUD.

What is Orthocell Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-9%

The average annual Cash from Operating Activities growth rates for Orthocell Ltd have been -13% over the past three years , -9% over the past five years .

Back to Top